FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to double agonists; it can be used in medicine. The invention makes it possible to obtain compounds that have agonistic activity against both the GLP-1 receptor (glucagon-like peptide 1) and the GLP-2 receptor (glucagon-like peptide 2).
EFFECT: invention can be used as a therapeutic agent in the prevention or treatment of intestinal damage or dysfunction, body weight regulation, as well as in the prevention or treatment of metabolic dysfunction in humans.
14 cl, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ACYLATED DOUBLE AGONISTS OF GLP-1/GLP-2 | 2017 |
|
RU2753193C2 |
| PHARMACEUTICAL PARENTERAL COMPOSITION OF DOUBLE AGONIST GLP1/2 | 2020 |
|
RU2815643C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY | 2013 |
|
RU2671088C2 |
